19 November 2014, 6:50 pm
A 12-week oral combination of sofosbuvir plus the experimental NS5A inhibitor GS-5816 demonstrated high sustained virological response rates for people with difficult-to-treat HCV genotype 3 and other genotypes, according to phase 2 study findings presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last week in Boston. Reducing treatment duration


19 November 2014, 8:50 am
The UK’s annual epidemiological report, released yesterday, shows that the country already provides HIV treatment to 90% of people attending clinical services and that 90% of those on treatment have an undetectable viral load. But the country has a long way to go in ensuring that people with HIV are aware of their HIV


17 November 2014, 6:50 am
People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – although even then the cure rate falls short of 10%, researchers reported on Tuesday at the American Association for the Study of


14 November 2014, 10:50 am
HPV vaccination programmes should be extended to gay and other men who have sex with men (MSM), an interim statement issued by the UK’s expert vaccine committee recommends. Vaccinating all MSM aged 16-40 years attending sexual health or HIV clinics would be cost effective, preventing both anal cancer and ano-genital warts. Vaccine campaigners have welcomed the


13 November 2014, 10:50 am
An all-oral regimen of grazoprevir (MK-5172) and elbasvir (MK-8742), taken with or without ribavirin for 12 weeks, demonstrated high sustained virological response (SVR) rates for treatment-naive and treatment-experienced people with genotype 1 hepatitis C virus (HCV), including people with liver cirrhosis and HIV and HCV co-infection, researchers reported on Tuesday at the American Association for the


1 2
LATEST VIDEOS

TAKE ACTION
UPCOMING EVENTS
    • No upcoming events
  • YOUR NEWS
  • View All Add your news
    YOUR PICTURES
  • LATEST TWEETS